End-to-End Gene and Cell Therapy CDMO ServicesMore
Suzhou Porton Biologics Ltd. always adheres to the service concept of “customer first”. We take full advantage of the state-of-art technology and equipment and create high-standard biological drug CRO and CDMO platforms. We are committed to providing robust and fast services to meet your CRO and CDMO needs in China and around the globe.
Portonbio announced strategic cooperation with KAEDI to accelerate the R&D and production of CAR-T drugs
Portonbio announced a strategic cooperation with KAEDI .Portonbio will offer CMC services for KAEDI’s CAR-T cell therapies with its end-to-end CDMO platform for gene and cell therapies to help accelerate their development process.
Porton Biologics Announces Closing Series-A Financing to Drive Commercial Production of Gene and Cell Therapy
On April 16, 2021, Suzhou Porton Biologics Ltd., which focuses on gene and cell therapy CDMO service, officially announced the closing of Series A funding round, which raised 400 million RMB. The participants of the financing include industry's top-tier investment institutions, SDIC and GL Ventures, HM Capital, Huashan Ruilian and Momentum Venture.
Porton Biologics will attend the BioPharmaceutical Innovation Technology Summit 2021
If you have any questions or comments about our business, please fill in the form below and we will contact you as soon as possible.